- Cellular Localization of RANKL and RANK Production in Giant Cell Tumors of Bone and Tendon Sheath by Immunohistochemistry
-
Cheong HR, Kang H, Song DE, Cho MS
- KMID: 1907771
- Ewha Med J.
- 2010 Mar;33(1):23-28.
- doi: 10.12771/emj.2010.33.1.23
No abstract available in English. -
- CITED
-
- Close
- SHARE
-
- Close
- Denosumab for the treatment of osteoporosis
-
McClung MR
- KMID: 2376998
- Osteoporos Sarcopenia.
- 2017 Mar;3(1):8-17.
- doi: 10.1016/j.afos.2017.01.002
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of... -
- CITED
-
- Close
- SHARE
-
- Close
- Signaling Pathways in Osteoclast Differentiation
-
Kim JH, Kim N
- KMID: 2152652
- Chonnam Med J.
- 2016 Jan;52(1):12-17.
- doi: 10.4068/cmj.2016.52.1.12
Osteoclasts are multinucleated cells of hematopoietic origin that are responsible for the degradation of old bone matrix. Osteoclast differentiation and activity are controlled by two essential cytokines, macrophage colony-stimulating factor... -
- CITED
-
- Close
- SHARE
-
- Close
- Osteoprotegerin and Osteoprotegerin Ligand Expression in the Periprosthetic Tissue of Failed Hip Prosthesis
-
Yoo MC, Cho YJ, Kim IW, Yang HI, Kim KI, Chun YS, Ko DO
- KMID: 2138622
- J Korean Orthop Assoc.
- 2004 Apr;39(2):155-161.
PURPOSE: To investigate the pathogenesis of articular prosthesis osteolysis, and to clarify the role of OPG, RANKL and RANK on osteolysis in aseptic loosening of hip prostheses. MATERIALS AND METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Salivary soluble receptor activator of nuclear factor kappa B ligand/osteoprotegerin ratio in periodontal disease and health
-
Tabari ZA, Azadmehr A, Tabrizi MA, Hamissi J, Ghaedi FB
- KMID: 2212031
- J Periodontal Implant Sci.
- 2013 Oct;43(5):227-232.
- doi: 10.5051/jpis.2013.43.5.227
PURPOSE: The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) system plays a significant role in osteoclastogenesis, activation of osteoclasts, and regulation of bone resorption. This study... -
- CITED
-
- Close
- SHARE
-
- Close
- Regulation of NFATc1 in Osteoclast Differentiation
-
Kim JH, Kim N
- KMID: 2170050
- J Bone Metab.
- 2014 Nov;21(4):233-241.
- doi: 10.11005/jbm.2014.21.4.233
Osteoclasts are unique cells that degrade the bone matrix. These large multinucleated cells differentiate from the monocyte/macrophage lineage upon stimulation by two essential cytokines, macrophage colony-stimulating factor (M-CSF) and receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappaB
-
Kyung TW, Lee JE, Shin HH, Choi HS
- KMID: 1103588
- Exp Mol Med.
- 2008 Feb;40(1):52-58.
- doi: 10.3858/emm.2008.40.1.52
Rutin, a glycoside of flavonol, inhibits osteoclast formation induced by receptor activator of NF-kappaB ligand (RANKL) in bone marrow-derived macrophages. It reduces reactive oxygen species produced by RANKL and its... -
- CITED
-
- Close
- SHARE
-
- Close
- Synovial RANKL/OPG mRNA Ratio and Effect of IL-17 in Experimental Rheumatoid Arthritis Model
-
Lee JH, Kim GT, Ryu S, Kim JI, Baek SH, Kim SI
- KMID: 1581082
- J Korean Rheum Assoc.
- 2006 Jun;13(2):123-131.
OBJECTIVE: To investigate the synovial mRNA expression of receptor activator of NFkappaB (RANK), RANK ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG mRNA expression ratio, and to evaluate the effects of IL-17... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
-
Min YK
- KMID: 2407099
- Endocrinol Metab.
- 2015 Mar;30(1):19-26.
- doi: 10.3803/EnM.2015.30.1.19
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts... -
- CITED
-
- Close
- SHARE
-
- Close
- Osteoclasts: Crucial in Rheumatoid Arthritis
-
Jeong WJ, Kim HJ
- KMID: 2326728
- J Rheum Dis.
- 2016 Jun;23(3):141-147.
- doi: 10.4078/jrd.2016.23.3.141
Osteoclasts are a major component of bone metabolism in physiologic condition and in rheumatoid arthritis (RA). RA is a chronic, autoimmune, inflammatory disease primarily affecting the joints. Joint inflammation leads... -
- CITED
-
- Close
- SHARE
-
- Close
- NFATc1 and NFATc3 is Involved in the Expression of Receptor Activator of NF-kappaB Ligand in Activated T Lymphocytes
-
Heo SJ, Park HJ, Baek JH
- KMID: 1431127
- Int J Oral Biol.
- 2013 Mar;38(1):37-42.
Receptor activator of NF-kappaB ligand (RANKL) is an essential cytokine for osteoclast differentiation, activation and survival. T lymphocytes such as T17 cells, a subset of T helper cells that produce... -
- CITED
-
- Close
- SHARE
-
- Close
- NF-kappaB-Mediated Regulation of Osteoclastogenesis
-
Boyce BF, Xiu Y, Li J, Xing L, Yao Z
- KMID: 2407101
- Endocrinol Metab.
- 2015 Mar;30(1):35-44.
- doi: 10.3803/EnM.2015.30.1.35
Osteoclasts are multinucleated cells formed mainly on bone surfaces in response to cytokines by fusion of bone marrow-derived myeloid lineage precursors that circulate in the blood. Major advances in understanding... -
- CITED
-
- Close
- SHARE
-
- Close
- Can denosumab be a substitute, competitor, or complement to bisphosphonates?
-
Kim SY, Ok HG, Birkenmaier C, Kim KH
- KMID: 2376043
- Korean J Pain.
- 2017 Apr;30(2):86-92.
- doi: 10.3344/kjp.2017.30.2.86
Osteoblasts, originating from mesenchymal cells, make the receptor activator of the nuclear factor kappa B ligand (RANKL) and osteoprotegerin (OPG) in order to control differentiation of activated osteoclasts, originating from... -
- CITED
-
- Close
- SHARE
-
- Close
- Hypoxia Inducible Factor-1α Directly Induces the Expression of Receptor Activator of Nuclear Factor-κB Ligand in Chondrocytes
-
Baek K, Park HJ, Baek JH
- KMID: 2162141
- Int J Oral Biol.
- 2016 Mar;41(1):9-15.
- doi: 10.11620/IJOB.2016.41.1.009
Receptor activator of nuclear factor-κB ligand (RANKL) is an osteoblast/stromal cell-derived essential factor for osteoclastogenesis. During endochondral bone formation, hypertrophic chondrocytes calcify cartilage matrix that is subsequently resorbed by osteoclasts... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of the arthritis related osteoporosis
-
Kwon SR, Park W
- KMID: 1984694
- Korean J Med.
- 2006 Jan;70(1):119-125.
The osteoporosis is frequently observed in the patients with the inflammatory arthritis and painful rheumatism. The treatment of the osteoporosis for them is different from that for the patients without... -
- CITED
-
- Close
- SHARE
-
- Close
- Intraarticular Corticosteroids Modulate the Osteoprotegerin/Receptor Activator of Nuclear Factor-kappaB Ligand System in the Synovial Fluid in Patients with Rheumatoid Arthritis
-
Lee JS, Suh JT
- KMID: 2106444
- J Korean Orthop Assoc.
- 2008 Apr;43(2):227-233.
- doi: 10.4055/jkoa.2008.43.2.227
PURPOSE: Despite the fact that intraarticular corticosteroids are a longstanding adjuvant treatment for inflammatory arthritis, their mechanisms of action are not completely understood. This study evaluated the osteoprotegerin (OPG) and... -
- CITED
-
- Close
- SHARE
-
- Close
- Isoliquiritigenin Inhibits Metastatic Breast Cancer Cell-induced Receptor Activator of Nuclear Factor Kappa-B Ligand/Osteoprotegerin Ratio in Human Osteoblastic Cells
-
Lee SK, Park KK, Kim KR, Kim HJ, Chung WY
- KMID: 2380881
- J Cancer Prev.
- 2015 Dec;20(4):281-286.
- doi: 10.15430/JCP.2015.20.4.281
Bone destruction induced by the metastasis of breast cancer cells is a frequent complication that is caused by the interaction between cancer cells and bone cells. Receptor activator of nuclear... -
- CITED
-
- Close
- SHARE
-
- Close
- Hypoxia Inducible Factor-1alpha Directly Induces the Expression of Receptor Activator of Nuclear Factor-kappaB Ligand in MLO-Y4 Osteocytes
-
Baek K, Park HJ, Baek JH
- KMID: 1789365
- Int J Oral Biol.
- 2015 Mar;40(1):19-25.
- doi: 10.11620/IJOB.2015.40.1.019
Osteocytes may function as mechanotransducers by regulating local osteoclastogenesis. Reduced availability of oxygen, i.e. hypoxia, could occur during disuse, bone development, and fracture. Receptor activator of nuclear factor-kappaB ligand (RANKL)... -
- CITED
-
- Close
- SHARE
-
- Close
- Fexaramine Inhibits Receptor Activator of Nuclear Factor-κB Ligand-induced Osteoclast Formation via Nuclear Factor of Activated T Cells Signaling Pathways
-
Zheng T, Kim NY, Yim M
- KMID: 2397553
- J Bone Metab.
- 2017 Nov;24(4):207-215.
- doi: 10.11005/jbm.2017.24.4.207
BACKGROUND: Osteoclasts are bone resorbing cells and are responsible for bone erosion in diseases as diverse as osteoporosis, periodontitis, and rheumatoid arthritis. Fexaramine has been developed as an agonist for... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression of Osteoprotegerin and Osteoclast Differentiation Factor in Human Periodontal Ligament Fibroblast Cells
-
Rew SH, Heo SR, Kim HS, Oh KO
- KMID: 2191749
- J Korean Acad Periodontol.
- 2002 Dec;32(4):721-731.
- doi: 10.5051/jkape.2002.32.4.721
Recently, soluble TNF receptor homolog osteoprotegerin (OPG) and its membrane-bound ligand osteoclast differentiation factor (ODF) were found to regulate osteoclast formation and function, and bone metabolism. It is now well... -
- CITED
-
- Close
- SHARE
-
- Close
